| SELL | 4.350 | David Baskin | The future isn't bright. Losing market share with their main product. Suggests tax loss selling. | 2007-10-23 | |
| DON'T BUY | 7.040 | Laura Wallace | Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent. | 2005-12-22 | |
| SELL | 8.100 | David Burrows | The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here. | 2005-11-11 | |
| DON'T BUY | 9.000 | John Zechner | The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen. | 2005-09-29 | |
| DON'T BUY | 10.000 | Gordon Higgins, CA, MBA, CFA | Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away. | 2005-08-11 | |
| WAIT | 11.890 | David Cockfield | Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through. | 2005-06-15 | |
| DON'T BUY | 12.590 | Norman Levine | A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition. | 2005-06-06 | |
| SELL | 13.020 | Norman Levine | Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in. | 2005-05-25 | |
| DON'T BUY | 15.370 | Ron Meisels | This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away. | 2005-04-11 | |
| DON'T BUY | 15.630 | David Cockfield | Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money. | 2005-03-10 | |
| WEAK BUY | 15.360 | John Zechner | Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product. | 2005-03-09 | |
| DON'T BUY | 18.810 | David Burrows | You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on. | 2005-02-15 | |
| DON'T BUY | 18.240 | John Zechner | Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline. | 2005-02-14 | |
| WAIT | 19.940 | Mark Jackson, CFA | Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales. | 2005-02-01 | |
| BUY | 20.050 | Andrew McCreath | Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects. | 2005-01-17 | |
| BUY | 20.980 | Robert Floyd | Strong balance sheet. Outlook for the sale of their product is quite encouraging. | 2005-01-07 | |
| DON'T BUY | 18.590 | Laura Wallace | Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong. | 2004-12-23 | |
| BUY | 19.000 | Robert Floyd | Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT. | 2004-12-17 | |
| DON'T BUY | 19.010 | Ron Meisels | Dropped below the 200 day moving average. | 2004-12-01 | |
| VAGUE | 18.220 | Michael Smedley | Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end. | 2004-11-25 | |
| DON'T BUY | 19.300 | John Zechner | Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term. | 2004-11-11 | |
| TOP PICK | 19.180 | Danny Tomka | Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash. | 2004-11-09 | |
| BUY | 19.080 | Gavin Graham | Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product. | 2004-11-08 | |
| DON'T BUY | 19.570 | Laura Wallace | Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive. | 2004-10-20 | |
| WEAK BUY | 20.550 | Ross Healey | Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application. | 2004-09-17 | |
| DON'T BUY | 20.550 | Ben Stadelmann | Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification. | 2004-09-16 | |
| DON'T BUY | 20.690 | Ian Nakamoto | Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson. | 2004-09-14 | |
| DON'T BUY | 19.160 | Andrew McCreath | Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future. | 2004-09-08 | |
| WEAK BUY | 21.360 | Danny Tomka | Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down. | 2004-08-26 | |
| VAGUE | 21.360 | Glenn Paradis, BA, CFA | More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited. | 2004-08-26 | |
| BUY on WEAKNESS | 21.840 | Martin Hubbes, CFA | At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players. | 2004-08-23 | |
| HOLD | 21.340 | David Baskin | The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying. | 2004-08-17 | |
| HOLD | 22.200 | Robert Floyd | The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace. | 2004-08-03 | |
| DON'T BUY | 23.970 | Matt Baillie | The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks. | 2004-07-30 | |
| BUY | 23.150 | Danny Tomka | Has dropped after the acquisition. Real cheap now. | 2004-07-22 | |
| DON'T BUY | 26.150 | Ron Meisels | Stock just broke below its 200 day moving average. That's a negative sign. | 2004-07-14 | |
| DON'T BUY | 25.090 | David Baskin | Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this. | 2004-07-07 | |
| DON'T BUY | 26.600 | Glenn Paradis, BA, CFA | Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma. | 2004-06-30 | |
| HOLD | 25.240 | David Baskin | Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006. | 2004-06-17 | |
| HOLD | 24.000 | Ian Nakamoto | Market didn't like news. Wait. | 2004-06-14 | |
| DON'T BUY | 31.510 | Mark Jackson, CFA | Good company. Well-run. Can't see a lot of upside in terms of news flow. | 2004-05-28 | |
| HOLD | 35.460 | John Sinkins, CFA | Very pleased with its performance. Has been very successful with its main product Visodine. Probably will be range bound for a while. Doesn't have a strong pipeline. Has a lot of cash flow so will be able to make acquisitions. | 2004-05-11 | |
| DON'T BUY | 39.130 | Andrew McCreath | Has had a big run and expects it to pause here for a little while. Have a lot of cash. Fully valued. | 2004-04-20 | |
| DON'T BUY | 37.200 | David Baskin | Getting more and more approvals from HMOs and insurance companies. Probably at a peak right now. Could retreat 10/15%. | 2004-04-13 | |
| BUY | 33.280 | Peter Brieger | Great story. Shares are fully priced. Dont own | 2004-03-31 | |
| BUY on WEAKNESS | 32.170 | Robert Floyd | Likes the company, but is waiting for the price to pull back into the $20's before buying it again. | 2004-03-25 | |
| BUY | 32.280 | Michael Sprung | Have had drug developments that have been going a lot better for them. Prefers biotech companies that have a broader product mix. Market outlook seems to be quite positive for them. | 2004-03-04 | |
| BUY | 31.240 | Gavin Graham | Visudine is approved for macular degeneration as well as ocular degeneration. Now making lots of money. | 2004-02-17 | |
| BUY | 33.000 | Gavin Graham | Own. Great technology. A lot to go. May have a bit of a pullback | 2004-02-03 | |
| DON'T BUY | 24.100 | David Baskin | Have had difficulty in getting broad exposure of their products in the US. The jury is still out on whether this is a long-term efficacious treatment or not. | 2004-01-22 | |
| BUY | 22.510 | Peter Brieger | The long-term outlook should be good based on their product or vision health. | 2004-01-20 | |
| BUY on WEAKNESS | 25.620 | Mark Jackson, CFA | Thinks are still a little bit of upside. Potential for growth. Would buy on weakness. | 2004-01-08 | |
| WEAK BUY | 24.800 | Peter Brieger | Expects the growth from visudine will be very strong. Buy for a three-year hold. | 2003-12-22 | |
| DON'T BUY | 24.520 | Brian Acker, CA | Model price is $24.83, so fully valued. Would consider at $21.40. | 2003-12-17 | |
| PAST TOP PICK | 24.600 | Ted Macklin | (A past top pick Sept 23/03. Up 5%.) Still likes. Has been volatile. Continue to believe in Visudine and the improved use of it. | 2003-12-16 | |
| TOP PICK | 20.290 | John Zechner | Suspects the price may mistakenly drop because of competitor coming out with a drug, but it will actually be used with QLT’s. Have had good earnings. The multiple in the high teens is really attractive. Have cash. Volatile | 2003-11-13 | |
| HOLD | 20.370 | Ted Macklin | A very volatile stock. The caveat is that it is a one trick pony. Healthcare stocks have pulled back quite a bit. | 2003-10-30 | |
| DON'T BUY | 20.700 | David Baskin | Have had good news recently in that their treatment for eye disease has been accepted by a number of US insurance companies. Probably fully priced now. | 2003-10-28 | |
| DON'T BUY | 21.940 | John Zechner | There have been a few negative developments this year. Fully valued. | 2003-10-02 | |
| TOP PICK | 23.500 | Ted Macklin | One trick pony however, they do have some tremendous potential for expansion of their Visodine product. Also expecting approval for funding for more expanded use of their product. | 2003-09-23 | |
| DON'T BUY | 23.290 | Laura Wallace | Has a very difficult time breaking the $24 mark. Has had a lot of good news. Does not look cheap on earnings basis. Could still have failure at the FDA trials. Risky. | 2003-09-19 | |
| PAST TOP PICK | 24.190 | Gavin Graham | (A top pick Aug 6/03. Up 3%.) Still likes. | 2003-09-18 | |
| BUY | 22.530 | Peter Brieger | OK to buy the long-term. Should be a terrific performer in the next 2/3 years. | 2003-09-17 | |
| BUY | 19.300 | Mike Weir | Should be able to move higher.Earnings should continue to grow.Could be a takeover. | 2003-08-19 | |
| BUY on WEAKNESS | 19.300 | David Baskin | A news driven stock.This sector is volatile, but this company has product and makes money.A pretty good company, but buy on the dips. | 2003-08-19 | |
| DON'T BUY | 19.450 | Bruce Campbell | It has demographics going for it.Visodine sales are ramping up a little.The easy money has been made.Starting to look a little bit expensive. | 2003-08-18 | |
| BUY | 19.820 | Andrew McCreath | Believes there are several catalysts in the next few months that potentially could make the shares move to a price level that would be higher than merited by their existing business. | 2003-08-15 | |
| BUY on WEAKNESS | 18.910 | Bruce Campbell | Had a good run.Would like to buy it a dollar or two cheaper. | 2003-08-11 | |
| TOP PICK | 21.920 | Gavin Graham | They are finding more and more uses for their product.Could be used in cancer treatment.World-class technology. | 2003-08-06 | |
| WEAK BUY | 23.920 | John Sinkins, CFA | Looking better. Fundamentals are good. Profitable. | 2003-07-28 | |
| BUY on WEAKNESS | 18.650 | Larry Berman CFA, CMT, CTA | Nice base pattern. Could be a little higher a year from now. | 2003-07-21 | |
| BUY | 17.630 | Ray Steele | Still has some good upside potential. | 2003-06-19 | |
| BUY | 18.950 | Nereo Piticco | Great product. Should be able to expand its one product or will be taken over. Good shape financially. | 2003-06-10 | |
| BUY on WEAKNESS | 18.950 | Mark Jackson, CFA | Was extremely cheap in the $11/12 range, but feels $17/18 may be a little high. Would like to see a pull back. | 2003-06-10 | |
| DON'T BUY | 17.680 | Richard Stone | Has a lot of work to do to break out and get moving again. | 2003-06-03 | |
| BUY | 15.790 | Gavin Graham | Some good products. Dropped recently on a drug (cancer) problem, but a minimal problem. | 2003-05-22 | |
| DON'T BUY | 16.180 | David Burrows | Very volatile. Sector is doing well but there are better companies. | 2003-05-13 | |
| BUY | 15.000 | John Sinkins, CFA | Good results on their Visodine. The future is bright. | 2003-03-31 | |
| BUY | 12.450 | Gavin Graham | Its a real company that has done really well. The stock price has not reflected it as yet. | 2003-03-05 | |
| DON'T BUY | 12.280 | Laura Wallace | Has trouble expanding its product use. Speculative. | 2003-02-03 | |
| DON'T BUY | 12.300 | Andrew McCreath | A one product company. | 2003-01-31 | |
| DON'T BUY | 11.820 | Richard Stone | Need to get settled in the US/European market places. Stock will be quiet over the next while. | 2003-01-30 | |
| BUY | 12.440 | John Zechner | Visudine sales numbers are coming out soon and expect they will be good. Their drug pipeline is expanding. Cheap. | 2003-01-21 | |
| DON'T BUY | 13.120 | David Baskin | Has had regulatory problems in Th US. Nervous on pharmaceuticals at this time. | 2003-01-14 | |
| DON'T BUY | 12.800 | Gordon Higgins, CA, MBA, CFA | Sales are poorer than expected.Trading at 20 X earnings. Has a history of missing their numbers. | 2003-01-10 | |
| DON'T BUY | 13.450 | Michael Sprung | Prefers others. A lot of competition. | 2003-01-06 | |
| WEAK BUY | 13.080 | Ted Macklin | A one trick pony. Same competition. | 2002-12-23 | |
| TOP PICK | 14.000 | Glenn Paradis, BA, CFA | Should be able to expand into new drugs. Growth in their Visodine should be good. | 2002-12-06 | |
| BUY | 12.700 | Gavin Graham | Has an interesting new drug. Got FDA approval for their eye drug. Price is down. | 2002-10-18 | |
| BUY on WEAKNESS | 12.160 | Richard Stone | Product is starting to broaden itself. Be patient. | 2002-10-10 | |
| DON'T BUY | 12.200 | David Burrows | Not a fan of pharmaceuticals and this one is not the best. | 2002-09-24 | |
| BUY | 12.000 | David Baskin | Has run into problems with US health agencies getting them to pay for the product. Should do OK. | 2002-09-23 | |
| DON'T BUY | 12.000 | Mark Jackson, CFA | Limited pipeline. Trying to expand. Has limited downside, but not much upside either. | 2002-09-23 | |
| BUY | 12.010 | John Zechner | They have $5 a share in cash. Good product. | 2002-09-19 | |
| HOLD | 12.240 | Brian Acker, CA | Has only one product. If it drops to $12.10, sell. | 2002-09-04 | |
| STRONG BUY | 12.180 | Mike Weir | Should move up significantly in the next 12/18 months. | 2002-08-26 | |
| DON'T BUY | 13.070 | Brian Acker, CA | Can't see any earnings. Could drop. | 2002-08-22 | |
| DON'T BUY | 12.100 | David Baskin | US Medicare is not recognizing it for health costs yet. They also need another product. | 2002-08-19 | |
| BUY | 13.680 | John Sinkins, CFA | Likes the company. Has had a rough time. | 2002-08-14 | |
| WEAK BUY | 16.130 | Ross Healey | Downside target was $15. Needs better earnings. If it goes over $18 it becomes speculative. | 2002-07-24 | |
Experts that have talked about QLT Inc
